Research Analysts Issue Forecasts for ZVRA FY2024 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at William Blair dropped their FY2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a report issued on Wednesday, November 13th. William Blair analyst S. Corwin now expects that the company will earn ($2.00) per share for the year, down from their previous forecast of ($1.58). William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share. William Blair also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.42) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.70) EPS.

Several other research analysts also recently weighed in on the stock. Canaccord Genuity Group decreased their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a research report on Friday, October 11th. JMP Securities started coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price target for the company. Guggenheim initiated coverage on Zevra Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $20.00 price objective on the stock. Finally, Roth Mkm increased their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Performance

ZVRA opened at $8.62 on Monday. The company’s 50 day moving average is $8.03 and its 200 day moving average is $6.50. The company has a current ratio of 2.88, a quick ratio of 2.00 and a debt-to-equity ratio of 0.84. The company has a market cap of $453.58 million, a price-to-earnings ratio of -4.38 and a beta of 1.93. Zevra Therapeutics has a 12-month low of $4.18 and a 12-month high of $9.21.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. During the same period in the previous year, the business posted ($0.40) earnings per share.

Institutional Trading of Zevra Therapeutics

Several institutional investors have recently made changes to their positions in the business. MetLife Investment Management LLC boosted its stake in Zevra Therapeutics by 8.1% in the 3rd quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock worth $159,000 after purchasing an additional 1,717 shares during the period. City State Bank boosted its position in shares of Zevra Therapeutics by 14.1% during the third quarter. City State Bank now owns 16,224 shares of the company’s stock worth $113,000 after acquiring an additional 2,000 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after acquiring an additional 2,452 shares in the last quarter. International Assets Investment Management LLC increased its holdings in Zevra Therapeutics by 594.0% in the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after acquiring an additional 5,940 shares during the last quarter. Finally, IFG Advisors LLC lifted its stake in Zevra Therapeutics by 41.2% in the 3rd quarter. IFG Advisors LLC now owns 26,400 shares of the company’s stock worth $183,000 after purchasing an additional 7,700 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.